Adjuvants and AI-driven formulation, according to Corteva doubles, “built-in”the role of the standalone adjuvants manufacturer is undergoing a silent but radical shift.
For decades, adjuvants were an afterthought—a tank-mix additive to fix drift or spread. However, based on insights from Corteva’s recent presentations at the FAT 2025 conference, the era of “active ingredient-centric” chemistry is giving way to a “formulation-centric” future. For adjuvant producers, this is no longer just about selling a surfactant; it is about providing data-compatible, renewable molecular tools.
The End of the “One-Size-Fits-All” Adjuvant
Corteva’s strategy reveals a clear destination: the future is a pre-mixed, high-performance cocktail where the adjuvant is “built-in” to boost uptake and reduce dosage .
To remain relevant, adjuvant manufacturers are pivoting from commodity products to specialized functional co-formulants. The market is demanding molecules that do more than just wet a leaf; they must enable low-use rates (e.g., Corteva’s Adavelt™ technology, which improves efficacy by 1.7x) and be compatible with complex pre-mixes of multiple actives .
Speaking the Language of “GenAE”
The biggest disconnect—and opportunity—lies in data. Corteva is deploying GenAE, a generative AI system that screens thousands of potential formulations in silico before a drop is mixed in a lab .
For an adjuvant producer, if your molecular data (viscosity, surface tension, biocompatibility) is not machine-readable or integrated into the cloud, your product will be invisible to the AI.
We are entering the age of “Digital Chemistry.” Leading producers are now providing digital twins of their adjuvant libraries. This allows Corteva’s algorithms to predict stability and performance instantly, compressing what used to be months of lab work into hours of computation .
The “Renewable” Mandate
Sustainability is no longer just a marketing claim; it is a technical specification. Corteva has implemented a “renewability factor” and a ranking system for over 4,500 adjuvant ingredients, prioritizing safety and bio-renewable content .
The chemistry required is complex. Replacing heavy aromatic solvents (like NMP) with bio-based alternatives without losing penetration power is the industry’s current Everest. As Corteva demonstrated with the Loyant™ NeoEC, renewable adjuvants can now rival traditional SC formulations in performance .
The Bottom Line for Suppliers
Corteva is moving toward a closed-loop innovation system. As they integrate biology (biostimulants) with chemistry, the need for adjuvants that are safe for both the plant biome and the environment is critical .
For the adjuvant manufacturer, the message is clear: Adapt or be disintermediated. The future belongs to those who can provide “green” chemistry that is smart enough to talk to AI and tough enough to work in a low-dose, high-efficacy Corteva formulation.
